contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


faron-pharmaceuticals-bexmab-studys-good-momentum-supports-valuation

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Antti Siltanen

Head of Nordic ER Development, Analyst

Antti Luiro

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Sure, sure. If phase 2 is implemented here, the rights to the data will certainly have a hefty price. Especially if high-quality data suitable for applications is produced. So there are no free lunches on offer, as one might infer from the message. Faron will likely provide information on the details of this collaboration once the deal is finalized.

Could Medsir still get money from treating patients? I mean, if it’s a for-profit company?

Why would Medsir fund research without any revenue?

If any future potential returns from Bex, such as royalties, were to be shared with MEDSIR or others through agreements, it would likely have to be announced via a stock exchange release. No such release has been issued, so that is not the case. Release 2.3.26: ”Bexmarilimab is Faron’s wholly owned, investigational immunotherapy”. And if we were already in the royalty phase for solid tumors, it would mean royalties from big pharma. They might not like it during contract negotiations if the rights were already scattered globally. If a randomized Phase 2 BEXAR trial of that scale—278 patients—were conducted as a multicenter study in Europe instead of at a single site, it could, with good results, qualify for conditional marketing authorization from the EMA. For the FDA, centers in the US are required. MEDSIR also has its reaches there. Regulators look at the quality of the data, not the sponsor. Before dreaming of further steps, the work must first begin, starting with the dose finding; that phase can probably be conducted in Barcelona alone. We are following the announcements.

Fees for the underwriting commitments have been paid, and due to the pricing of the offering and the share price, the fee is likely quite large.

These Faron webcasts have so far had the flaw that they don’t allow difficult questions to be asked. Hopefully, the situation will be different on March 17th.

The prospectus isn’t out yet; it will apparently be released this evening or tomorrow morning at the latest. Hopefully, it will clarify why Faron will net only slightly over 32 million euros from a 40 million euro offering. The lead manager bank doesn’t charge such large fees, so is it some HCM loan arrangement, or does Faron have to pay extra fees to those parties that provided guarantees to ensure the success of the offering? The advance commitments to participate in the offering were only about 11 million euros. This probably indicates that institutions didn’t have much appetite for this round; they were still actively involved in the 30 million public offering in 2024. If this 8 million euro mystery isn’t solved in the prospectus, the company management will definitely be questioned about it in the March 17th webcast.

Faron Pharmaceuticals

Faron again published positive results of the BEXMAB study that focuses on blood cancers. The company seems to have preliminary efficacy proof already in the phase I/II study, which we believe...

<p>Faron again published positive results of the BEXMAB study that focuses on blood cancers. The company seems to have preliminary efficacy proof already in the phase I/II study, which we believe supports the probabilities of the study path being successful. With the positive estimate changes justified by the results we feel that the valuation picture of the share is slightly more neutral, but still not sufficiently attractive in terms of the risk/return ratio. </p> 

	2022	23e	24e
Revenue	0.0	0.0	0.0
growth-%
EBIT (adj.)	-27.4	-15.8	-3.1
EBIT-% (adj.)	-685,650.0 %	-394,522.5 %	-76,864.0 %
EPS (adj.)	-0.46	-0.24	-0.05
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Faron Pharmaceuticals: BEXMAB study’s good momentum supports valuation

Key Estimate Figures17.04.2023

Forum discussions